Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2009-3-6
pubmed:abstractText
In order to assess ovarian pathological changes and their relationship to changes in female fertility parameters, mifepristone, a progesterone receptor antagonist, was selected as the test article and was administered orally to female rats at dose levels of 0, 0.8, 4, 20 and 100 mg/kg for 2 or 4 weeks in repeated dose-toxicity studies and in a female fertility study at dose levels of 0, 0.8, 4 and 20 mg/kg from > 2 weeks before copulation to postcoital day 7. In the repeated dose toxicity studies, persistent estrus was seen in the vaginal smears, and multiple cysts in the ovaries at necropsy, increases in luteinized cysts and hypertrophy of previously formed corpora lutea were observed in the histopathological examination of ovaries in rats receiving 20 mg/kg or more for 2 or 4 weeks. In female fertility studies, persistent vaginal cornification was also observed at 20 mg/kg and the precoital interval was significantly shortened. All of the animals were completely infertile when dosed with 20 mg/kg during the post-coital period. An increase in pre-implantation losses was observed in the animals treated with 20 mg/kg during the pre-coital phase, while treatment with 4 mg/kg mifepristone during the post-coital phase induced an increase in post-implantation losses. These results suggested that a 2-week administration period would be sufficient to detect the ovarian toxicity of mifepristone in repeated dose toxicity study and the pathological findings in the ovaries would reflect the alterations in female reproductive endpoints in the female fertility study.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1880-3989
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
34 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
SP31-42
pubmed:meshHeading
pubmed-meshheading:19265287-Administration, Oral, pubmed-meshheading:19265287-Animals, pubmed-meshheading:19265287-Drug Administration Schedule, pubmed-meshheading:19265287-Embryonic Development, pubmed-meshheading:19265287-Estrous Cycle, pubmed-meshheading:19265287-Female, pubmed-meshheading:19265287-Fertility, pubmed-meshheading:19265287-Hormone Antagonists, pubmed-meshheading:19265287-Infertility, Female, pubmed-meshheading:19265287-Japan, pubmed-meshheading:19265287-Male, pubmed-meshheading:19265287-Mifepristone, pubmed-meshheading:19265287-Ovarian Cysts, pubmed-meshheading:19265287-Ovary, pubmed-meshheading:19265287-Pregnancy, pubmed-meshheading:19265287-Public-Private Sector Partnerships, pubmed-meshheading:19265287-Rats, pubmed-meshheading:19265287-Rats, Sprague-Dawley, pubmed-meshheading:19265287-Societies, Scientific, pubmed-meshheading:19265287-Specific Pathogen-Free Organisms, pubmed-meshheading:19265287-Toxicity Tests, pubmed-meshheading:19265287-Vagina
pubmed:year
2009
pubmed:articleTitle
Collaborative work on evaluation of ovarian toxicity. 2) Two- or four-week repeated dose studies and fertility study of mifepristone in female rats.
pubmed:affiliation
Toxicology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Azumino, Nagano, Japan. toru_tamura@pharm.kissei.co.jp
pubmed:publicationType
Journal Article